Ozuriftamab BA302 represents a significant advancement in cancer management. This unique antibody-drug conjugate specifically targets B-cell maturation antigen, a key protein expressed on patients with multiple myeloma cells and some hematologic types. Its mechanism of action involves deliveri
cyclohexamide & Naramycin A inhibit protein synthesis through differing mechanisms. cyclohexamide functions as a potent inhibitor of eukaryotic proteins synthesis , binding to the ribosomal subunit at the acceptor site and preventing amino acid incorporation. Naramycin , conversely, specifically
Raxibacumab, medically designated as PAmAb ABthrax, is a groundbreaking therapeutic approach for the infection. This single antibody , developed by ProBioGen AG , specifically